PSG finally reach Champions League holy grail and have potential for dominance
When Marquinhos hoisted aloft the trophy that mattered more to PSG than any other, it was the culmination of a chase that had lasted more than a decade.
Since the club's transformative takeover in 2011, the number one target for Paris Saint-Germain had been both clear and elusive.
Advertisement
Previously, French football had just one Champions League winner and even that triumph for Marseille was clouded in controversy given the events that followed. Qatar Sports Investment were determined to give one of Europe's greatest cities one of the continent's finest football teams. Now, that status is confirmed.
It has been an arduous road to European success, one that has seen PSG come close, fail, and garner little popularity. Galactico regimes saw transfer records broken and incredible individual talent assembled, but the current iteration of PSG has seen a collection of superstars evolved into a superstar collective.
The elephants in the room remain. PSG are a state-owned club who have decimated the competitive balance in France, but from a purely football perspective they've been a breath of fresh air this season. Even in France, the Parisians entered Saturday's showdown with Inter with the well wishes of some neutrals.
Advertisement
Credit must go to Luis Enrique, who enjoys the adulation of the PSG fanbase. Their tifo at the Allianz Arena honouring the Spaniard's late daughter, Xana, was a touching moment.
Last summer, Enrique lost Kylian Mbappe to Real Madrid. The forward's free transfer exit to Spain saw PSG's record scorer leave but from out of Mbappe's shadow has stepped superstars aplenty. Footage emerged last season of Enrique demanding more from Mbappe defensively, a team-first philosophy that has been evident among his replacements this season.
In Munich on Saturday, Ousmane Dembele stood in a sprinter's stance whenever Inter prepared to take a goal-kick, ready to lead a suffocating Parisian press from the front. Elsewhere, Achraf Hakimi celebrated one recovery run more so than his opening goal. Khvicha Kvaratskhelia, meanwhile, covered hard yards late on to stop an Inter counter, despite PSG's comfortable lead.
Enrique has built a side of talent and teamwork. In almost every position on the pitch, PSG have a footballer who can claim to be among the world's best in their role. Yet there seems to be no clashes of personality or ego.
Their final performance against Inter will reverberate around world football. Never before has there been such a one-sided decider. Inter, with the oldest average age in this season's competition, looked like a side overawed, overpowered and outclassed. It was ecstasy for PSG, torture for their opponents. Five unanswered goals and the biggest final winning margin in the history of this competition.
Advertisement
The scary thing for rival sides is that this PSG team may not yet have reached its peak. The fourth-youngest squad in this season's Champions League, only Marquinhos of the 16 players who featured in the final is over thirty.
Desire Doue became the first teenager to score twice in a Champions League final, while also adding an assist for the opener. The Frenchman turns 20 on Tuesday and will do so with a Champions League winner's medal draped around his neck.
Signed from Rennes last summer, he is the poster boy of PSG's new recruitment model. On the rise, exhilarating, and fearless. In just one season, he's evolved from a Ligue 1 prospect to a big-game decider. He was not the only one to come of age.
Real Madrid, Barcelona and Bayern Munich will come again. Liverpool, Arsenal and Manchester City too will invest heavily this summer. Next season's Champions League should be a fascinating watch but there's little doubt that PSG will be the team to beat again.
Advertisement
Nasser Al-Khelaifi's ambition to create Europe's best team is complete.
Read – Every record PSG broke or equalled in historic Champions League final
See more – The biggest Champions League final wins ever as PSG set new record
Follow The Football Faithful on Social Media:
Facebook | Instagram | Twitter | YouTube | TikTok
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
San Francisco Chronicle
28 minutes ago
- San Francisco Chronicle
Brian Priske returns to Sparta Prague as coach after a stint at Feyenoord
PRAGUE (AP) — Brian Priske has agreed to return to Sparta Prague on a multiple-year contract after a stint at Feyenoord, the Czech club said. Priske started at Sparta three years ago and immediately led the struggling team to its first title in nine years. He successfully defended the title last year and completed a double by winning the Czech Cup. Under Priske, Sparta reached the round of 16 in the Europa League where it was eliminated by Liverpool in the 2023-24 season. Last summer, Sparta agreed to release Priske before the end of his contract to take over at Feyenoord when Arne Slot became the Liverpool manager. Priske led Feyenoord in 33 games in all competitions, won the Dutch Super Cup and advanced from the league phase of the Champions League but was fired in February due to inconsistent results in the domestic league. ___
Hamilton Spectator
30 minutes ago
- Hamilton Spectator
Brian Priske returns to Sparta Prague as coach after a stint at Feyenoord
PRAGUE (AP) — Brian Priske has agreed to return to Sparta Prague on a multiple-year contract after a stint at Feyenoord, the Czech club said. Priske started at Sparta three years ago and immediately led the struggling team to its first title in nine years. He successfully defended the title last year and completed a double by winning the Czech Cup. Under Priske, Sparta reached the round of 16 in the Europa League where it was eliminated by Liverpool in the 2023-24 season. Last summer, Sparta agreed to release Priske before the end of his contract to take over at Feyenoord when Arne Slot became the Liverpool manager . Priske led Feyenoord in 33 games in all competitions, won the Dutch Super Cup and advanced from the league phase of the Champions League but was fired in February due to inconsistent results in the domestic league. Priske replaces his former assistant Lars Friis , who was fired after Sparta's fourth-place finish in the Czech league. 'Now, I'm back with at least the same hunger as before — maybe even more,' Priske said. ___ AP soccer:
Yahoo
34 minutes ago
- Yahoo
Bladder Cancer Drug Market Forecast and Analysis Report 2025: Focus on US, France, Germany, Italy, Spain, UK, Japan, and China - Epidemiology, Pipeline Therapies, 10 Year Forecasts
Explore the comprehensive "Bladder Cancer: Eight-Market Drug Forecast and Market Analysis" report, covering the 8 major markets (US, France, Germany, Italy, Spain, UK, Japan, China). Gain insights into disease epidemiology, 10-year patient-based forecasts, and market trends, as well as late-stage pipeline therapies set to drive market growth. Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "Bladder Cancer: Eight-Market Drug Forecast and Market Analysis" report has been added to Highlights Report deliverables include a Pdf report and Excel-based forecast model Forecasts includes the 8MM Forecasts covers from 2021-2031 The analyst valued the bladder cancer market in the 8MM at $2.39 billion and expects the market to increase to $2.89 billion by 2031 Incyte, GSK and CTI BioPharma are expected to take market-leading position in 2031 A moderate level of unmet need will remain for most bladder cancer patient populations during the forecast period The late-stage pipeline in bladder cancer is robust and is likely to provide significant clinical benefit to many bladder cancer patient populations, with fierce competition expected This report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for bladder cancer. These sales forecasts leverage data on pharmaceutical sales and drug availability from the analyst's World Markets Healthcare (WMH) and POLI Price Intelligence being a rare blood cancer, MF is a blockbuster market and is expected to grow from sales of $2.39 billion in 2021 to $2.89 billion in 2031, at a compound annual growth rate (CAGR) of 1.9%. Peak-year sales are set to be reached in 2027, driven by the approvals of several promising late-stage pipeline agents and the continued clinical dominance of Jakafi/Jakavi (ruxolitinib). In 2028, Jakafi/Jakavi is set to come off-patent in the US, which will greatly decrease its total market sales. However, the loss of total market sales will be somewhat recuperated in 2028 and beyond by the additional growth in market value of other pipeline Janus kinase (JAK) inhibitors and targeted therapies, with sales of these agents being driven by ameliorating critical unmet needs within the MF treatment markets across the 8MM will experience growth driven by common drivers: Approvals of late-stage pipeline agents, including novel JAK inhibitors and targeted therapies, which will partially meet critical unmet clinical needs Decreased reliance on generic immunomodulatory agents, androgens, and erythropoietin-stimulating agents Increased utilization of novel combination regimens with premium-priced agents Common barriers to market growth experienced across the 8MM primarily include a series of patent expiries: Patent expiry of Jakafi/Jakavi Patent expiry of Vonjo (pacritinib) Patent expiry of Inrebic (fedratinib) Key Highlights This report covers the eight major markets (8MM: US, France, Germany, Italy, Spain, the UK, Japan and China). The report provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends. Key topics covered include a strategic competitive assessment of current and future drugs, unmet needs, KOL insights, and implications for the severe asthma market. The base year of the sales forecast model is 2023, and the forecast period is 2023-2033. Scope Overview of bladder cancer, including epidemiology, symptoms, diagnosis, and disease management. Annualized bladder cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033. Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the bladder cancer therapeutics market. Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for bladder cancer treatment. The most promising candidates in Phase III and Phase IIb development are profiled. Analysis of the current and future market competition in the global bladder cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications Reasons to Buy Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the global bladder cancer therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global bladder cancer therapeutics market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships Key Topics Covered: Abbreviations Related Reports Executive Summary Disease Overview Overview of Bladder Cancer Bladder Cancer Market Strength, Weakness, Opportunity, and Threat Analysis Epidemiology Diagnosed Incident Cases Both Sexes Age-Specific Diagnosed Incident Cases Sex-Specific Diagnosed Incident Cases Diagnosed Incident Cases by Type, Sex, Age Diagnosed Incident Cases by Stage at Diagnosis Diagnosed Incident Cases by Tumor Stage at Diagnosis Diagnosed Incident Cases of Stage Ta Bladder Cancer by Grade Diagnosed Incident Cases of Stage of Bladder Cancer by Broad Classification Diagnosed Incident Cases of Stage of NMIBC by Risk Group Diagnosed Incident Cases of Bladder Cancer by Mutations and Biomarkers Five-Year Diagnosed Prevalent Cases of Bladder Cancer Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Tumor Stage Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Broad Classification Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Relapse or Recurrence Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Treatment Disease Management Treatment Guidelines Treatment Paradigm - First-Line Therapy in Non-Muscle Invasive Bladder Cancer Treatment Paradigm - First-Line Therapy in Muscle Invasive Bladder Cancer Treatment Paradigm - Locally Advanced/Metastatic Bladder Cancer KOL Insight on the Bladder Cancer Treatment Algorithm Unmet Needs and Opportunities Unmet Needs in Bladder Cancer Competitive Landscape Assessment Pipeline Drugs Overview Competitive Landscape Methodology Competitive Assessment - Intravesical Delivered Therapies for NMIBC Competitive Assessment - Gene Therapies for NMIBC Competitive Assessment - Antibody-Drug Conjugates Market Outlook Bladder Cancer Market Forecast Bladder Cancer Market Forecast by Class Bladder Cancer Market Drivers and Barriers Appendix Primary Research: KOL Information Sources Used and Not Used to Forecast Diagnosed Incident Cases Sources Used to Forecast Diagnosed Incident Cases by Stage at Diagnosis Sources Used to Forecast Diagnosed Incident Cases by Tumor Stage at Diagnosis Sources Used to Forecast Diagnosed Incident Cases of Stage Ta Bladder Cancer by Grade Sources Used to Forecast Diagnosed Incident and Five-Year Diagnosed Prevalent Cases by Broad Classification Sources Used to Forecast Diagnosed Incident Cases of NMIBC by Risk Group Sources Used to Forecast Diagnosed Incident Cases by Mutations and Biomarkers Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases by Relapse or Recurrence Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases by Treatment Sources and Methodology Epidemiological Forecast Insight Strengths and Limitations A selection of companies mentioned in this report includes, but is not limited to: AstraZeneca Merck Bristol-Myers Squibb Gilead Sciences LLC Roche Pfizer Immunomedics Inc Astellas Pharma Co Ltd Johnson & Johnson Daiichi Sankyo Co Ltd Ferring Pharmaceuticals Ltd ImmunityBio Inc BeiGene Ltd Bicycle Therapeutics Inc CG Oncology Inc Shanghai Miracogen Inc Fidia farmaceutici SpA Therlase Inc enGene Holdings Inc UroGen Pharma Inc For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
